Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin

(2022) Mario E Lacouture et al.   ONCOLOGIST

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

(2021) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

(2021) Evan Y Yu et al.   LANCET ONCOLOGY

KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

(2021) Christopher J. Hoimes et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

(2021) Thomas Powles et al.   LANCET ONCOLOGY

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

(2021) David J Straus et al.   Lancet Haematology

Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis

(2021) Alicia K. Morgans et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum-Refractory Advanced Urothelial Carcinoma

(2020) Umang Swami et al.   JOURNAL OF UROLOGY

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

(2020) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

(2019) Y Fradet et al.   ANNALS OF ONCOLOGY

Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting

(2019) Jason C. Simeone et al.   Cancer Epidemiology

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

(2019) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

989TiPKEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

(2019) M Galsky et al.   ANNALS OF ONCOLOGY

First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis

(2019) Ravi B Parikh et al.   Future Oncology

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

(2018) Craig H. Moskowitz et al.   BLOOD

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

(2017) Arjun V Balar et al.   LANCET ONCOLOGY

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

(2016) R. Chen et al.   BLOOD

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

(2016) P. M. Challita-Eid et al.   CANCER RESEARCH

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

(2016) V.R. Belum et al.   EUROPEAN JOURNAL OF CANCER

Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

(2011) Matthew D. Galsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

(2011) Maria De Santis et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986

(2009) Maria De Santis et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER